Uricemia in the acute phase of myocardial infarction and its relation to long-term mortality risk
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F21%3AN0000049" target="_blank" >RIV/00064190:_____/21:N0000049 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/21:10428345 RIV/00216208:11140/21:10428345
Result on the web
<a href="http://dx.doi.org/10.2217/cer-2021-0082" target="_blank" >http://dx.doi.org/10.2217/cer-2021-0082</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/cer-2021-0082" target="_blank" >10.2217/cer-2021-0082</a>
Alternative languages
Result language
angličtina
Original language name
Uricemia in the acute phase of myocardial infarction and its relation to long-term mortality risk
Original language description
Although uric acid has antioxidant effects, hyperuricemia has been established as an indicator of increased cardiovascular mortality in various patient populations. Treatment of asymptomatic hyperuricemia in patients with acute myocardial infarction (MI) is not routinely recommended, and the efficacy of such treatment in terms of cardiovascular risk reduction remains doubtful. Materials & methods: In a prospective cohort study, we followed 5196 patients admitted for a MI between 2006 and 2018. We assessed the relationship between baseline uricemia and the incidence of all-cause death and cardiovascular mortality and the effect of long-term allopurinol treatment. Hyperuricemia was defined as serum uric acid >450 mu mol/l in men and >360 mu mol/l in women. Results: In the entire cohort, the 1-year all-cause and cardiovascular mortality rates were 8 and 7.4%, and the 5-year rates were 18.3 and 15.3%, respectively. Using a fully adjusted model, hyperuricemia was associated with a 70% increased risk of both all-cause death and cardiovascular mortality at 1 year, and the negative prognostic value of hyperuricemia persisted over the 5-year follow-up (for all-cause death, hazard risk ratio = 1.45 [95% CI: 1.23-1.70] and for cardiovascular mortality, hazard risk ratio = 1.52 [95% CI: 1.28-1.80], respectively). Treatment of asymptomatic hyperuricemia with allopurinol did not affect mortality rates. Conclusion: Hyperuricemia detected in patients during the acute phase of an MI appears to be independently associated with an increased risk of subsequent fatal cardiovascular events. However, hyperuricemia treatment with low-dose allopurinol did not prove beneficial for these patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
ISSN
2042-6305
e-ISSN
2042-6313
Volume of the periodical
10
Issue of the periodical within the volume
12
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
979-988
UT code for WoS article
000659984900001
EID of the result in the Scopus database
2-s2.0-85111130203